WallStSmart

The Cooper Companies, Inc (COO)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

The Cooper Companies, Inc generates 27% more annual revenue ($4.24B vs $3.33B). WST leads profitability with a 17.0% profit margin vs 13.5%. COO appears more attractively valued with a PEG of 0.52. COO earns a higher WallStSmart Score of 71/100 (B).

COO

Strong Buy

71

out of 100

Grade: B

Growth: 6.7Profit: 5.5Value: 8.0Quality: 6.5
Piotroski: 4/9Altman Z: 2.65

WST

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

COOUndervalued (+60.4%)

Margin of Safety

+60.4%

Fair Value

$209.49

Current Price

$55.29

$154.20 discount

UndervaluedFair: $209.49Overvalued
WSTSignificantly Overvalued (-45.7%)

Margin of Safety

-45.7%

Fair Value

$168.92

Current Price

$371.09

$202.17 premium

UndervaluedFair: $168.92Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COO4 strengths · Avg: 9.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

EPS GrowthGrowth
357.1%10/10

Earnings expanding 357.1% YoY

PEG RatioValuation
0.528/10

Growing faster than its price suggests

Operating MarginProfitability
20.8%8/10

Strong operational efficiency at 20.8%

WST3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Operating MarginProfitability
22.5%8/10

Strong operational efficiency at 22.5%

Areas to Watch

COO2 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.6%4/10

0.6% revenue growth

Return on EquityProfitability
6.8%3/10

ROE of 6.8% — below average capital efficiency

WST3 concerns · Avg: 2.7/10
Price/BookValuation
8.7x4/10

Trading at 8.7x book value

PEG RatioValuation
2.822/10

Expensive relative to growth rate

P/E RatioValuation
46.3x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : COO

The strongest argument for COO centers on Price/Book, EPS Growth, PEG Ratio. PEG of 0.52 suggests the stock is reasonably priced for its growth.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.

Bear Case : COO

The primary concerns for COO are Revenue Growth, Return on Equity.

Bear Case : WST

The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 46.3x leaves little room for execution misses.

Key Dynamics to Monitor

COO profiles as a value stock while WST is a mature play — different risk/reward profiles.

WST carries more volatility with a beta of 1.14 — expect wider price swings.

WST is growing revenue faster at 13.8% — sustainability is the question.

COO generates stronger free cash flow (273M), providing more financial flexibility.

Bottom Line

COO scores higher overall (71/100 vs 61/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

The Cooper Companies, Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?